Rapport Therapeutics Inc

RAPP

Healthcare|Biotechnology|USA

$41.79

-0.25 (-0.60%)

Tangible Book

$9.86

About

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Stock Price

+171.7%(1Y)

Pipeline Summary

5 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 4Completed: 1

Active Trials (4)

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07594119Focal Seizure

Phase 3Recruiting

Enrollment: 312 participants

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

NCT07046494Bipolar 1 Disorder

Phase 2Recruiting

Enrollment: 250 participants

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881Focal Seizure

Phase 3Recruiting

Enrollment: 333 participants

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407Focal Epilepsy

Phase 2Recruiting

Enrollment: 30 participants

BioScore

5.3/10

Watchlist

Ownership

Recent Insider Trades

Gault CherylSELL

2026-06-3010,000 shares @ $41.58

Ceesay AbrahamSELL

2026-06-298,220 shares @ $39.83

Third Rock Ventures V, L.P.SELL

2026-05-2618,572 shares @ $40.05

Third Rock Ventures V, L.P.SELL

2026-05-11133,618 shares @ $40.24

Third Rock Ventures V, L.P.SELL

2026-05-08276,513 shares @ $40.12

Recent News

2026-07-01 22:05:31

2026-06-24 19:30:31

Data last updated: Jul 13, 2026, 12:43 PM